{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:23:23Z","timestamp":1788819803069,"version":"build-2803163510"},"reference-count":26,"publisher":"Informa UK Limited","issue":"38","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.2217\/fon-2022-0923","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T10:49:11Z","timestamp":1671187751000},"page":"4161-4170","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":18,"title":["Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-1071","authenticated-orcid":false,"given":"Jorge E","family":"Cortes","sequence":"first","affiliation":[{"name":"Leukemia, Georgia Cancer Center,Augusta University,\rAugusta,\rGA 30912,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[{"name":"Hematology and Internal Oncology,Universit\u00e4tsklinikum Jena,\rJena,\r07747,\rGermany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology,Akita University,\rAkita City,\r010-8502,\rJapan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Larson","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology,University of Chicago,\rChicago,\rIL 60637,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghayas C","family":"Issa","sequence":"additional","affiliation":[{"name":"Leukemia,The University of Texas MD Anderson Cancer Center,\rHouston,\rTX 77030,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Bombaci","sequence":"additional","affiliation":[{"name":"CML Patients Group,CML Advocates Network,\rTurin,\r10124,\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Ramscar","sequence":"additional","affiliation":[{"name":"Clinical Development Medical Director,Novartis Pharma AG,\rBasel,\rCH-4056,\rSwitzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Ifrah","sequence":"additional","affiliation":[{"name":"Global Trial Director,Novartis Pharma AG,\rParis,\r92563,\rFrance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P","family":"Hughes","sequence":"additional","affiliation":[{"name":"Hematology,South Australian Health & Medical Research Institute & University of Adelaide,\rAdelaide,\rSA,\r5001,\rAustralia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.253"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00048-4"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1905447"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2"},{"key":"e_1_3_4_8_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia. V1 (2023). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00603"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62120-0"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01589-y"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137393"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01055-9"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106458"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature21702"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01040"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902328"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009984"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1174"},{"key":"e_1_3_4_23_1","volume-title":"EHA 2022.","author":"R\u00e9a D","year":"2022","unstructured":"R\u00e9a D , HochhausA, MauroMJet al. Efficacy and safety results from ASCEMBL, a phase III study of asciminib vs bosutinib in patients with chronic myeloid leukemia in chronic phase after \u22652 prior tyrosine kinase inhibitors: week 96 update. Presented at: EHA 2022.Vienna, Austria and virtual (2022). June 9\u201317,"},{"key":"e_1_3_4_24_1","volume-title":"ASCO.","author":"R\u00e9a D","year":"2022","unstructured":"R\u00e9a D , MauroMJ, HochhausAet al. Efficacy and safety results from ASCEMBL, a phase III study of asciminib vs bosutinib in patients with chronic myeloid leukemia in chronic phase after \u22652 prior tyrosine kinase inhibitors: week 96 update. Presented at: ASCO.Chicago, IL and virtual (2022). June 3\u20137"},{"key":"e_1_3_4_25_1","unstructured":"Scemblix (asciminib) . Prescribing information.Novartis Pharmaceuticals Corporation (2021). www.novartis.us\/sites\/www.novartis.us\/files\/scemblix.pdf (Accessed August 23 2022)."},{"key":"e_1_3_4_26_1","unstructured":"ClinicalTrials.gov . A study of oral asciminib versus other TKIs in adult patients with newly diagnosed Ph+ CML-CP. (Accessed August 23 2022). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04971226"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3495"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/bimj.201000239"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-0923","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T02:46:34Z","timestamp":1719110794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-0923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":26,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.2217\/fon-2022-0923"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-0923","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}